Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Twilio Inc (TWLO) Price & Performance

Charles River Laboratories Intl. IncTrade
Twilio IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Twilio Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $232.53 (market cap $11.14B), while Twilio Inc trades at $220.37 (market cap $33.06B). The key difference: Twilio Inc is far larger — about 3× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Twilio Inc nearer its low. Which is the better fit depends on your goals.

CRLTWLO
Market Cap
$11.14B$33.06B
Sector
HealthTechnology
52-Week High
$233.60$236.64
52-Week Low
$145.57$92.44
Enterprise Value
$14.00B$31.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Twilio Inc

Twilio (TWLO) trades at $218.24, up 1.72% today, showing strong momentum after recent earnings beats. The stock is in a bullish technical trend with support at $212 and resistance at $223. Revenue grew to $5.07B in 2025, with net income turning positive at $33.83M, signaling a successful turnaround. Analyst sentiment is overwhelmingly positive, with 77% recommending Buy and a consensus price target of $215.14. Operating cash flow reached $1.0B, reflecting improved financial health.

Outlook: Twilio's AI-driven communication tools and margin expansion under CEO Khozema Shipchandler support growth, but high valuation multiples (P/E 330.67) pose risks. Competition and execution challenges remain key concerns. The stock offers upside if earnings momentum continues, yet volatility near 52-week highs warrants caution.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Twilio Inc

Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

Read more on TWLO